Investigational Drug Information for Gedatolisib
✉ Email this page to a colleague
What is the development status for investigational drug Gedatolisib?
Gedatolisib is an investigational drug.
There have been 12 clinical trials for Gedatolisib.
The most recent clinical trial was a Phase 1 trial, which was initiated on September 30th 2022.
The most common disease conditions in clinical trials are Breast Neoplasms, Triple Negative Breast Neoplasms, and Pancreatic Neoplasms. The leading clinical trial sponsors are Pfizer, Celcuity, Inc., and Eastchester Center for Cancer Care.
There are one hundred and fifteen US patents protecting this investigational drug and zero international patents.
Summary for Gedatolisib
| US Patents | 115 |
| International Patents | 1,571 |
| US Patent Applications | 608 |
| WIPO Patent Applications | 388 |
| Japanese Patent Applications | 72 |
| Clinical Trial Progress | Phase 1 (2022-09-30) |
| Vendors | 57 |
Recent Clinical Trials for Gedatolisib
| Title | Sponsor | Phase |
|---|---|---|
| Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer | Celcuity Inc | Phase 1/Phase 2 |
| Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer | Celcuity, Inc. | Phase 3 |
| Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1) | Celcuity, Inc. | Phase 3 |
Clinical Trial Summary for Gedatolisib
Top disease conditions for Gedatolisib
Top clinical trial sponsors for Gedatolisib
US Patents for Gedatolisib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Gedatolisib | ⤷ Subscribe | Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity | The University of North Carolina at Chapel Hill (Chapel Hill, NC) | ⤷ Subscribe |
| Gedatolisib | ⤷ Subscribe | Low, immune enhancing, dose mtor inhibitors and uses thereof | Novartis AG (Basel, CH) | ⤷ Subscribe |
| Gedatolisib | ⤷ Subscribe | Triazine compounds as PI3 kinase and mTOR inhibitors | Pfizer Inc. (New York, NY) | ⤷ Subscribe |
| Gedatolisib | ⤷ Subscribe | Solid forms of (1S,4S)-4-(2-(((3S,4R)-3-fluorotetrahydro-2H-pyran-4-yl)amino)-8-((2,4,6-- trichlorophenyl)amino)-9H-purin-9-yl)-1-methylcyclohexane-1-carboxamide and methods of their use | Signal Pharmaceuticals, LLC (San Diego, CA) | ⤷ Subscribe |
| Gedatolisib | ⤷ Subscribe | Treatment of myelodysplastic syndromes with 2-O and,or 3-O desulfated heparinoids | Cantex Pharmaceuticals, Inc. (Weston, FL) | ⤷ Subscribe |
| Gedatolisib | ⤷ Subscribe | Compounds and combinations for the treatment of HIV | Gilead Sciences, Inc. (Foster City, CA) | ⤷ Subscribe |
| Gedatolisib | ⤷ Subscribe | Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using the same | Pfizer Inc. (New York, NY) | ⤷ Subscribe |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Gedatolisib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Gedatolisib | Australia | AU2015244171 | 2034-04-11 | ⤷ Subscribe |
| Gedatolisib | Australia | AU2015244179 | 2034-04-11 | ⤷ Subscribe |
| Gedatolisib | Canada | CA2945128 | 2034-04-11 | ⤷ Subscribe |
| Gedatolisib | Canada | CA2945129 | 2034-04-11 | ⤷ Subscribe |
| Gedatolisib | China | CN106414451 | 2034-04-11 | ⤷ Subscribe |
| Gedatolisib | China | CN106459063 | 2034-04-11 | ⤷ Subscribe |
| Gedatolisib | European Patent Office | EP3129377 | 2034-04-11 | ⤷ Subscribe |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
